Carfilzomib Based Treatment Strategies in the Management of Relapsed/Refractory Multiple Myeloma with Extramedullary Disease
Open Access
- 22 April 2020
- Vol. 12 (4), 1035
- https://doi.org/10.3390/cancers12041035
Abstract
Published experience with carfilzomib in patients with relapsed/refractory multiple myeloma (RRMM) and extramedullary disease (EMD) is still limited. The current study aimed to assess the efficacy and safety of carfilzomib containing therapy regimens in EMD. We retrospectively analyzed 45 patients with extramedullary RRMM treated with carfilzomib from June 2013 to September 2019. The median age at the start of carfilzomib was 64 (range 40–80) years. Twenty (44%) and 25 (56%) patients had paraosseous manifestation and EMD without adjacency to bone, respectively. The serological overall response rate (ORR) was 59%. Extramedullary response was evaluable in 33 patients, nine (27%) of them achieved partial remission (PR) (ORR = 27%). In 15 (33%) patients, we observed no extramedullary response despite serological response. The median progression-free survival (PFS) and overall survival (OS) were five (95% CI, 3.5–6.5) and ten (95% CI, 7.5–12.5) months, respectively. EMD without adjacency to bone was associated with a significantly inferior PFS (p = 0.004) and OS (p = 0.04) compared to paraosseous lesions. Carfilzomib based treatment strategies showed some efficacy in heavily pretreated patients with extramedullary RRMM but could not overcome the negative prognostic value of EMD. Due to the discrepancy between serological and extramedullary response, evaluation of extramedullary response using imaging is mandatory in these patients.Keywords
This publication has 46 references indexed in Scilit:
- Extramedullary disease in multiple myeloma – controversies and future directionsBlood Reviews, 2019
- Cytogenetics in multiple myeloma patients progressing into extramedullary diseaseEuropean Journal of Haematology, 2015
- CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional ActivationCell Reports, 2015
- Features of Extramedullary Disease of Multiple Myeloma: High Frequency of P53 Deletion and Poor Survival: A Retrospective Single-Center Study of 834 CasesClinical Lymphoma Myeloma and Leukemia, 2015
- Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantationBritish Journal of Haematology, 2015
- Cytogenetics of extramedullary manifestations in multiple myelomaBritish Journal of Haematology, 2013
- Extramedullary multiple myelomaLeukemia & Lymphoma, 2012
- Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like featuresBlood, 2012
- Soft-Tissue Plasmacytomas in Multiple Myeloma: Incidence, Mechanisms of Extramedullary Spread, and Treatment ApproachJournal of Clinical Oncology, 2011
- Insights into extramedullary tumour cell growth revealed by expression profiling of human plasmacytomas and multiple myelomaBritish Journal of Haematology, 2003